O’Kane, Grainne M
Ezzat, Shereen
Joshua, Anthony M.
Bourdeau, Isabelle
Leibowitz-Amit, Raya
Olney, Harold J.
Krzyzanowska, Monika
Reuther, Dean
Chin, Soo
Wang, Lisa
Brooks, Kelly
Hansen, Aaron R.
Asa, Sylvia L.
Knox, Jennifer J.
Article History
Received: 12 January 2019
Revised: 12 April 2019
Accepted: 24 April 2019
First Online: 20 May 2019
Competing interests
: The authors declare no competing interests.
: This study was approved by the University Health Network (UHN) Research Ethics Board (REB) and submitted at each participating site. REB protocol number 08-0108. All patients provided informed consent as per study protocol. This consent included patient consent to collect clinical, demographic, genetic and outcome data for study publication. This study was conducted in accordance with the Declaration of Helsinki.
: This study is available withinthis publication and in the supplementary material. Further patient data can be requested from the corresponding author.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
: This study was funded as part of an Investigator Initiated Trial from Pfizer Canada. Dr Jennifer Knox, the Principal Investigator was the study sponsor.